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thrombocytopenic	 purpura	 (TTP)	 and	 atypical	 hemolytic	 uremic	 syndrome	 (aHUS).	
Deficiency	 of	ADAMTS13	 and	 dysregulation	 of	 the	 complement	 pathway	 result	 in	
TTP	and	aHUS,	respectively;	however,	overlap	of	their	clinical	characteristics	makes	
differential	diagnosis	challenging.
Objectives and Methods: We	aimed	to	develop	a	TMA	diagnosis	workflow	based	on	
ADAMTS13	activity	and	screening	of	ADAMTS13	and	complement	genes	using	a	cus-
tom	next-	generation	sequencing	(NGS)	gene	panel.
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1  | INTRODUCTION
Thrombotic	microangiopathies	 (TMAs)	 are	 characterized	 by	micro-




in	TTP,	 neurological	manifestations	 are	more	 common,	whereas,	 in	
aHUS,	renal	involvement	is	more	pronounced.	However,	this	rule	is	
not	always	reliable;	some	aHUS	patients	have	neurological	complica-
tions	and	some	TTP	patients	have	renal	failure.1–4 Over the last de-
cade,	noteworthy	progress	has	been	made	to	improve	the	clinical	and	
laboratory	approaches	to	predict	the	expected	signs	and	symptoms,	
patient	 outcome,	 and	 genotype-	phenotype	 correlations.	 Despite	
this,	the	differential	diagnosis	of	TTP/aHUS	remains	challenging.
TTP	 is	 caused	 by	 a	 severe	 plasma	 deficiency	 (i.e,	 <10%	 of	 the	
normal)	 of	 the	 cleaving	 protease	 of	 von	Willebrand	 factor	 (VWF)-	
ADAMTS13	 (a	 disintegrin	 and	 metalloproteinase	 with	 a	 thrombo-
spondin	 type	1	motif,	member	13).	A	severe	ADAMTS13	deficiency	
is	 more	 often	 due	 to	 anti-	ADAMTS13	 autoantibodies	 (acquired)	 or	
rarely	 due	 to	 homozygous	 or	 compound	 heterozygous	ADAMTS13	
gene	 mutations	 (hereditary,	 also	 called	 Upshaw-	Schulman	 syn-
drome).5,6	However,	heterozygosity	for	ADAMTS13 mutations was ob-
served	among	patients	diagnosed	with	acute	acquired	TTP	and	severe	
ADAMTS13	 deficiency.7,8	 In	 all	 forms,	 the	 predominant	 pathogenic	
factor	of	TTP	is	the	increased	number	of	ultra-	large	multimers	of	VWF	
resulting	 from	the	 lack	of	proteolytic	 regulation	by	ADAMTS13	and	
leading	to	platelet	clumping	in	the	microcirculation	of	various	organs.6
TTP	 is	 mainly	 an	 autoimmune	 disorder	 associated	 with	 severe,	
acquired	 ADAMTS13	 deficiency	 with	 the	 annual	 incidence	 rate	 of	
2.17×106	people	per	year,	although	hereditary	TTP	accounts	for	<5%	
of	all	ADAMTS13	deficient	TTP	cases,9	except	 in	certain	geographic	
locations,	 e.g,	 Central	 Norway,	 where	 hereditary	 TTP	 seems	 to	 be	
more	common	than	the	acquired	form.10
While	 TTP	 is	 characterized	 by	 the	 severe	 deficiency	 of	
ADAMTS13,	aHUS	 is	characterized	by	hyperactivation	of	 the	alter-
native	complement	pathway	resulting	from	either	a	loss-	of-	function	
mutation	 in	 a	 regulatory	 gene	 (CFH,	CFI,	CD46	 (MCP),	 or	THBD)	 or	
a	gain-	of-	function	mutation	in	an	effector	gene	(CFB or C3).1,11 The 
mutations	were	mainly	found	in	the	heterozygous	state,	and	approx-
imately	 5%	 of	 patients	 have	 combined	 mutations,	 usually	 in	 CFH 
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thrombocytopenia,	 anemia,	 and	 morphological	 evidence	 of	 red	 cell	
fragmentation.	 Sixty-	three	 patients	 were	 diagnosed	 in	 our	 depart-
ment	and	the	remaining	91	patients	were	referred	from	external	cent-
ers	 in	 different	 regions	 of	 Portugal.	 These	 hospitals	 diagnosed	 and	
treated	patients	with	TMA	and	sent	samples	to	our	center	to	perform	
ADAMTS13	 activity	 assay	 and/or	 genetic	 screening	 of	ADAMTS13	
and	 complement	 genes.	 Eight	 patients	 were	 excluded	 as	 their	
ADAMTS13	assay	sample	was	sent	after	the	administration	of	plasma	
or	initiation	of	plasma	exchange	(PEX).
The 146 individuals in this study included both adults and chil-
dren	with	a	median	age	of	36	years	 (1	month	through	89	years)	and	





Forty-	two	 healthy	 volunteers	 acted	 as	 a	 control	 group	 for	
ADAMTS13	assay	measurements	and	were	also	investigated	for	gene	
variants	with	the	NGS	panel.	The	control	group	included	unrelated	in-
dividuals	 (32	 females	 and	10	males)	without	 an	 individual	 or	 family	
history	of	excessive	bleeding,	thrombosis	or	hemolytic	anemia,	with	a	
mean	age	of	33.5±11.12	years.
We	also	 investigated	10	asymptomatic	 relatives	of	5	patients	 in	
whom an ADAMTS13	 mutation	 had	 been	 identified.	 In	 accordance	
with	 the	 Declaration	 of	 Helsinki,	 informed	 consent	 was	 obtained	
from	all	patients	or	from	their	family	members	and	from	the	healthy	
controls.
2.2 | Samples and sample processing
ADAMTS13	assays	were	performed	on	blood	collected	into	vacuum	








patient	 plasma	 and	 normal	 plasma	 (1:1	 dilution),25 and the residual 
ADAMTS13	activity	of	the	mixture	is	measured	using	TECHNOZYM	




Genomic	 DNA	 was	 extracted	 from	 EDTA	 whole	 blood	 by	 au-
tomatic	 isolation	 on	 an	 iPrep	 instrument	 using	 a	 gDNA	 Blood	 Kit	
(Thermo	Fisher	Scientific,	Waltham,	Massachusetts,	USA).	The	DNA	
concentration	was	adjusted	to	a	range	of	25-	50	ng/μL.
2.3 | Strategy for mutation analysis
Two	different	direct	sequencing	methodologies	were	used	for	the	mo-









year,	we	 developed	 a	 custom	 gene	 panel	 that	 includes	ADAMTS13,	





Before	 its	 implementation,	 the	 gene	 panel	 was	 validated	 using	
samples	from	8	patients	(TTP	and	aHUS)	previously	studied	by	Sanger	






by	 an	 intrinsic	 resistance	 of	VWF	 to	 proteolysis	 by	ADAMTS13	due	
to	possible	mutations	in	specific	VWF	cleavage	site	region	in	VWFA2	
domain.
Regarding	 to	 comparison	 between	 laboratories	 on	 the	 basis	 of	
coverage	and	diagnostic	yield	of	NGS,	 these	samples	were	analyzed	
to ADAMTS13	 ROIs	 using	 other	 NGS	 panel,	 as	 described	 in	 the	
Supplementary	Materials.
2.4 | Library preparation and NGS
The	 sequencing	 libraries	were	prepared	using	 the	AmpliSeq	 Library	
Kit	2.0,	and	pooled	barcoded	libraries	were	clonally	amplified	by	Ion	
OneTouch2	 both	 following	 the	 manufacturer’s	 protocol	 (Thermo	






Torrent	 Suite	 (v3.6;	 Thermo	 Fisher	 Scientific),	 and	 sequences	were	
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the	 pathogenic	mutations,	 and,	 finally,	 their	 validation	 by	 Sanger	 se-
quencing	were	 in	 accordance	with	 those	 previously	 described	 in	 our	
recent	work26,27	and	explained	in	detail	in	the	Supplementary	Materials.






3.1 | Characteristics of the patients studied







IgG	 antibodies	 level	 with	 a	 median	 titer	 of	 62	UA/mL	 (range:	 15-	




















panel	 only	 revealed	 common	variants	with	 a	minor	 allele	 frequency	
(MAF)	value	of	>1%	in	the	1000	Genomes.
3.2 | Identification of gene defects in TMA patients 
by NGS
The	NGS	method	confirmed	all	variants	previously	detected	by	Sanger	


































of the acute episode
TTP
(A) ADAMTS13 activity* ≈ 40%
(37-53%) (n=4)
(B) ADAMTS13 activity* normal
(n=32)




CFI,	CFB,	 and	CFHR5)	 (Figure	2)	whose	MAF	 in	 the	 different	 popu-
lations	 studied	 in	 the	 1000	Genomes	were	 below	1%.	The	 in	 silico	





identified	in	CFHR3,	CFHR4,	THBD,	and	DGKE in this cohort.
3.3 | Potential functional impact of novel variants
Seven	 of	 the	 8	 novel	 variants	 (89%)	 were	 pathogenic:	 5	 missense	



















Cleaves Tyr-Met bond Binds vWF A2 domain Thrombospondin repeats
N SP P M D 1 Cys Spacer 2 3 4 5 6 7 8 CUB CUB C
Regulatory  domain Recognition  domain
C3b Proteoglycans Proteoglycans C3b C3b
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p.Pro256Serfs*12;	 and	 CD46	 c.800-	821del,	 Thr267Ilefs*24).	 The	
remaining	 variant	 was	 indicated	 to	 be	 a	 likely	 benign	 variant	 (CFH 
c.1864A>G,	p.Ile622Val)	(Table	S3).
3.4 | Phenotype- genotype analysis in TTP patients
Four	putative	pathogenic	ADAMTS13	variants	(1	novel)	were	identi-
fied	 in	 the	7	hereditary	TTP	patients	of	 this	 cohort	 (5	with	disease	





the	 blood	 groups	 were	 analyzed,	 which	 revealed	 that	 all	 patients	
homozygous	 for	 this	mutation	were	of	 genotypic	blood	group	0101 
(Table	1).	 Likewise,	 the	analysis	of	12	 frequent	SNPs	 in	ADAMTS13 
showed	 that	 the	 most	 prevalent	 pathogenic	 mutation	 (c.2260T>C,	
p.Cys754Arg,	chr=9)	were	associated	with	the	same	haplotype	(Table	
S4).	The	 fact	 that	 the	9	mutation-	carrier	 chromosomes	are	 in	 com-





deficiency	in	remission	had	5	heterozygous	ADAMTS13 rare variants: 
pathogenic	(n=2),	likely	pathogenic	(n=1),	and	compound	heterozygous	





















allelesNucleotide Change Amino Acid Change VCe Zygosity Ref.






P2a F 5 Recurrence	with	infections PI 12 PI,	2U 
3/3	weeks
O1O1 c.2260T>C p.Cys754Arg P Homozygous [30] p.	Gln448Glu
f 0 1 0
P3a F 5 Recurrence	with	infections PI;	BPL	8Y 8 BPL	8Yd
3/3	weeks
O1O1 c.2260T>C p.Cys754Arg P Homozygous [30] p.Gln448Glu





PI;	BPL	8Y 3 No O1O1 c.2260T>C p.Cys754Arg P Homozygous [30] p.Gln448Glu
f 0 0 0
P5a M 7 m Recurrence	with	infections PI 4 No O1O1 c.2260T>C p.Cys754Arg P Homozygous [30] p.Gln448Glu
f 0 1 0














p.Gln448Glu 1 1 0
P7b F 26 Pregnancy PEX;PI 4 PI,	2U 
3/3	weeks
BB c.3368G>A p.Arg1123His P Homozygous [31] — 0 1 0
P8c M 20 No PEX;PI 0 No O1A1 c.1370C>T p.Pro457Leu P Heterozygous [32,33] p.Gln448Glu 
p.Ala900Val
0 2 0
P9c F 25 1	episode-	with	acute	
infection
PEX;PI 0 No O1A1 c.2914C>T p.Arg972Trp P Heterozygous [29] p.Ala900Val 0 0 0














— 0 0 0
P11c F 28 1	episode-	with	acute	
infection

















3.5 | Phenotype- genotype analysis in aHUS patients
In	17	out	of	34	(50%)	aHUS	patients’	mutations	were	 identified,	13	
patients	 had	 mutations	 in	 heterozygous	 state	 and	 4	 patients	 were	
compound	heterozygous.	Two	patients	presented	3	variants	in	a	sin-
gle	gene	 (CFH)	and	the	remaining	2	patients	had	combined	variants	
in	2	different	complement	genes	(C3/CFI and C3/CD46).	 In	total,	23	
rare	variants	 (7	non-	previously	described)	were	 identified	 in	6	com-
plement	genes	that	were	located	mostly	in	CFH	(12),	with	4	in	CD46,	
4 in C3,	1	in	CFI,	1	in	CFB,	and	1	in	CFHR5	(Table	2;	Figure	2).	Eleven	
variants	were	putative	 pathogenic,	 3	 likely	were	pathogenic,	 1	was	













with	a	 single	 likely	pathogenic	CFHR5	variant	were	homozygous	 for	
the CFHR1- 3	 deletion	 and	 the	 patient	 P14	 carrying	 a	 single	 benign	
C3	variant	was	homozygous	for	a	block	of	4	ADAMTS13	SNPs.	These	
additional	genetic	risk	factors	(with	impact	 in	the	activity	and	secre-
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ing	 for	 genetic	 TMA	 susceptibility	 factors	 using	 a	 successfully	 de-





Regarding	ADAMTS13	 variants	 in	 hereditary	TTP,	 our	 data	were	
in	 agreement	with	 2	 findings	 in	 previously	 reported	 studies44:	 first,	
homozygous	 variants	 in	 the	 N-	terminal	 ADAMTS13	 region	 (p.Ar-




of	 onset	 of	 26	years;	 second,	 siblings	 and	 unrelated	 patients	 with	
the	same	genotype	had	a	similar	age	of	disease	onset.8 The remain-










CFH- H3  
alleles
CFHR1- 3  
alleles
Nucleotide 
Change Amino Acid Change VCb Zygosity Ref.












— 1 0 1
P2 F 39 G PEX 0 CFH c.335A>G p.Tyr112Cys P Heterozygous Novel — 2 1 0
P3 F 45 PI 0 CFH c.493G>T p.Asp165Tyr P Heterozygous Novel — 1 1 1
P4 F 67 post	surgery PEX 0 CFH c.1864A>G p.Ile622Val LB Heterozygous Novel p.Gln448Glu 1 0 0
P5 F 35 PI 0 CFH c.2850G>T p.Gln950His P Heterozygous [12] — 0 0 1












— 2 1 0
P7 F 30 No PEX,	PI 
Eculizumab
1 CFH c.3562A>G p.Lys1188Glu P Heterozygous Novel — 0 1 0
P8 M 2 No PI 1 CFH c.3644G>T p.Arg1215Leu P Heterozygous Novel 0 0 2 0
P9 F 64 No PI 0 CFHR5 c.329T>C p.Val110Ala LP Heterozygous (pdb) — 1 0 2
P10 M 35 T PI, 
prednisolone
3 CD46 (MCP) c.287-	2A>G P Heterozygous [39] p.Gln448Glu	
p.Ala900Val
1 1 1
P11 M 4 G PI 0 CD46 (MCP) c.800_821del p.Thr267Ilefs*24 P Heterozygous Novel — 1 1 1
P12 M 37 No PI, 
Eculizumab
0 CD46 (MCP) c.1148C>T p.Thr383Ile B Heterozygous [40] — 2 1 2
P13 M 4 No PI 2 C3 c.193A>C p.Lys65Gln P Heterozygous [41] — 2 0 1





P15 F 33 G PEX,	prednisolone 
Eculizumab























0 1 1 0
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obvious	 deleterious	 consequences.	 However,	 patients	 carrying	 the	




relates with the same ADAMTS13	haplotype	and	blood	group	O1O1,	
suggesting	a	common	origin	and	high	prevalence	in	central	Portuguese	
population,	 in	 similarity	 with	 that	 described	 recently	 in	 central	
Norwegian	population.10
After	acute	episodes	in	the	4	TTP	patients	who	had	an	ADAMTS13 
rare	variant	and	anti-	ADAMTS13	 IgG	antibodies,	antibody	 levels	 re-
turned	to	normal	and	ADAMTS13	activity	increased	to	median	37.5%	
(range	35-	38),	and	this	could	be	explained	by	their	heterozygosity.	Two	
variants	 carried	 by	 these	 patients,	 p.Pro457Leu	 and	 p.Arg1096His,	
were	 previously	 found	 to	 be	 associated	 with	 acquired	 ADAMTS13	
deficiency.7,23,32,33	 Expression	 studies	 revealed	 reduced	ADAMTS13	







mutations	 in	 the	 population	 (confirmed	 in	 our	 local	 healthy	 con-
trols),	the	number	of	heterozygous	mutation	carriers	among	TTP	pa-
tients	 with	 severe	 acquired	 ADAMTS13	 deficiency	 suggests	 a	 role	
TABLE  2 Phenotypic	and	genotype	characteristics	of	17	patients	with	atypical	hemolytic	uremic	syndrome	carrying	rare	variants	in	 
complement	genes
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that	 other	 factors	 could	 influence	 this	 autoimmune	 disease,	 i.e,	 the	





These	 were	 predominantly	 loss-	of-	function	 variants	 in	 the	 com-
plement	 regulator	 genes	CFH,	CFHR5,	CD46,	 and	CFI	 (78%)	 along	
with	 gain-	of-	function	 variants	 in	 the	 complement	 inductor	 genes	
C3	(18%)	and	CFB	(4%).	CFH	variants	(12/23,	52%)	will	be	the	most	
prevalent	 in	 aHUS	 patients,	 as	 described	 in	 large	 studies	 in	 other	
populations.47–49
Likewise,	the	well-	documented	cumulative	effect	of	different	ge-
netic	risk	factors	for	the	aHUS	phenotype14,15,50 was also observed in 
our	patients:	compound	heterozygous	in	CFH	(2/12,	17%);	combined	
variants	 in	more	 than	 1	 gene	 (2/17,	 12%);	 combination	 of	 variants	
with	the	concomitant	presence	of	both	risk	haplotypes,	CFH- H3 and 




analyses	 of	ADAMTS13	 in	 our	 aHUS	 cohort	 revealed	 only	 common	
variants	(SNPs):	Gln448Glu,	the	most	prevalent	(20%)	and	p.Arg7Trp,	
p.Gln448Glu,	p.Pro618Ala,	and	p.Ala732Val,	co-	inherited	in	1	patient.	
The	 Gln448Glu	 variant	 alone	 had	 little	 impact	 but,	 conversely,	 the	
block	of	 these	4	SNPs	has	been	shown	 to	have	a	higher	 impact	on	
ADAMTS13	activity.39
Nevertheless,	 this	 NGS	 study	 ended	 with	 17	 (50%)	 genetically	
unresolved	aHUS	patients,	as	described	 in	others	aHUS	studies.14,48 
Therefore,	 the	 expectation	 that	 the	 whole-	exome	 sequencing	 ap-
proaches	could	 identify	other	genes	 involved	 in	aHUS	 is	high;	how-





come	 crucial	 for	 understanding	 the	 great	 inter-	individual	 variability.	
Therefore,	NGS-	targeted	gene	panels	have	changed	the	paradigm	of	
routine	molecular	studies.	In	the	face	of	the	multiple	genetic	changes	
found	 in	 every	 patient,	 the	 critical	 challenge	 was	 discriminating	
disease-	associated	variants	from	the	broader	background	of	variants	
present	in	all	patients’	genomes.51–55
In	 conclusion,	 the	 study	 of	 these	 77	 TMA	 Portuguese	 patients	
contributes	to	the	better	understanding	of	the	molecular	genetics	of	
ADAMTS13/complement	 gene-	related	 phenotypes.	 Moreover,	 our	
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